VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Histologically or cytologically confirmed          │ Histologically or cytologically confirmed          │     100 │
│ adenocarcinoma of the breast with locally advanced │ adenocarcinoma of the breast with locally advanced │         │
│ or metastatic disease, and a candidate for         │ or metastatic disease, and a candidate for         │         │
│ chemotherapy                                       │ chemotherapy                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Human epidermal growth factor receptor 2           │ Human epidermal growth factor receptor 2           │     100 │
│ (HER2)-positive                                    │ (HER2)-positive                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No prior chemotherapy for their metastatic breast  │ No prior chemotherapy for their metastatic breast  │     100 │
│ cancer (MBC)                                       │ cancer (MBC)                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Measurable disease                                 │ Measurable disease                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age ≥ 18 years                                     │ Age ≥ 18 years                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For women of childbearing potential and men with   │ For women of childbearing potential and men with   │     100 │
│ partners of childbearing potential, agreement to   │ partners of childbearing potential, agreement to   │         │
│ use a highly effective, non-hormonal form of       │ use a highly effective, non-hormonal form of       │         │
│ contraception or 2 effective forms of non-hormonal │ contraception or 2 effective forms of non-hormonal │         │
│ contraception by the patient and/or partner.       │ contraception by the patient and/or partner.       │         │
│ Contraception use must continue for the duration   │ Contraception use must continue for the duration   │         │
│ of study treatment and for at least 6 months after │ of study treatment and for at least 6 months after │         │
│ the last dose of study treatment. Male patients    │ the last dose of study treatment. Male patients    │         │
│ whose partners are pregnant should use condoms for │ whose partners are pregnant should use condoms for │         │
│ the duration of the study                          │ the duration of the study                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of any chemotherapy for MBC                │ History of any chemotherapy for MBC                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ An interval of \< 6 months from the completion of  │ An interval of < 6 months from the completion of   │     100 │
│ cytotoxic chemotherapy in the neo-adjuvant or      │ cytotoxic chemotherapy in the neo-adjuvant or      │         │
│ adjuvant setting until the time of metastatic      │ adjuvant setting until the time of metastatic      │         │
│ diagnosis                                          │ diagnosis                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Trastuzumab ≤ 21 days prior to randomization       │ Trastuzumab ≤ 21 days prior to randomization       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current peripheral neuropathy of Grade ≥ 3         │ Current peripheral neuropathy of Grade ≥ 3         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of other malignancy within the last 5      │ History of other malignancy within the last 5      │     100 │
│ years, except for appropriately treated carcinoma  │ years, except for appropriately treated carcinoma  │         │
│ in situ of the cervix, non-melanoma skin           │ in situ of the cervix, non-melanoma skin           │         │
│ carcinoma, Stage I uterine cancer, or other        │ carcinoma, Stage I uterine cancer, or other        │         │
│ cancers with a similar outcome as those previously │ cancers with a similar outcome as those previously │         │
│ mentioned                                          │ mentioned                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous radiotherapy for the treatment of         │ Previous radiotherapy for the treatment of         │     100 │
│ unresectable, locally advanced or metastatic       │ unresectable, locally advanced or metastatic       │         │
│ breast cancer is not allowed if more than 25% of   │ breast cancer is not allowed if more than 25% of   │         │
│ marrow-bearing bone has been irradiated or the     │ marrow-bearing bone has been irradiated or the     │         │
│ last fraction of radiotherapy has been             │ last fraction of radiotherapy has been             │         │
│ administered within approximately 3 weeks prior to │ administered within approximately 3 weeks prior to │         │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Brain metastases that are untreated, symptomatic,  │ Brain metastases that are untreated, symptomatic,  │     100 │
│ or require therapy to control symptoms or any      │ or require therapy to control symptoms or any      │         │
│ radiation, surgery, or other therapy to control    │ radiation, surgery, or other therapy to control    │         │
│ symptoms from brain metastases within 2 months     │ symptoms from brain metastases within 2 months     │         │
│ prior to randomization                             │ prior to randomization                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current unstable angina                            │ Current unstable angina                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of symptomatic congestive heart failure,   │ History of symptomatic congestive heart failure,   │     100 │
│ or ventricular arrhythmia requiring treatment      │ or ventricular arrhythmia requiring treatment      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of myocardial infarction within 6 months   │ History of myocardial infarction within 6 months   │     100 │
│ prior to randomization                             │ prior to randomization                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Left ventricular ejection fraction (LVEF) below    │ Left ventricular ejection fraction (LVEF) below    │     100 │
│ 50% within approximately 28 days prior to          │ 50% within approximately 28 days prior to          │         │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of decreased LVEF or symptomatic           │ History of decreased LVEF or symptomatic           │     100 │
│ congestive heart failure (CHF) with previous       │ congestive heart failure (CHF) with previous       │         │
│ adjuvant trastuzumab treatment                     │ adjuvant trastuzumab treatment                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cardiac troponin I ≥ 0.2 ng/mL within 28 days of   │ Cardiac troponin I ≥ 0.2 ng/mL within 28 days of   │     100 │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe dyspnea at rest because of complications of │ Severe dyspnea at rest because of complications of │     100 │
│ advanced malignancy or requiring current           │ advanced malignancy or requiring current           │         │
│ continuous oxygen therapy                          │ continuous oxygen therapy                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current severe, uncontrolled systemic disease (eg, │ Current severe, uncontrolled systemic disease (eg, │     100 │
│ clinically significant cardiovascular, pulmonary,  │ clinically significant cardiovascular, pulmonary,  │         │
│ or metabolic disease; wound healing disorders;     │ or metabolic disease; wound healing disorders;     │         │
│ ulcers; or bone fractures)                         │ ulcers; or bone fractures)                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major surgical procedure or significant traumatic  │ Major surgical procedure or significant traumatic  │     100 │
│ injury within approximately 28 days prior to       │ injury within approximately 28 days prior to       │         │
│ randomization or anticipation of the need for      │ randomization or anticipation of the need for      │         │
│ major surgery during the course of study treatment │ major surgery during the course of study treatment │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current pregnancy or lactation                     │ Current pregnancy or lactation                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of receiving any investigational treatment │ History of receiving any investigational treatment │     100 │
│ within approximately 28 days prior to              │ within approximately 28 days prior to              │         │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current known infection with human                 │ Current known infection with human                 │     100 │
│ immunodeficiency virus (HIV), active hepatitis B   │ immunodeficiency virus (HIV), active hepatitis B   │         │
│ and/or hepatitis C virus                           │ and/or hepatitis C virus                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of intolerance (including Grade 3-4        │ History of intolerance (including Grade 3-4        │     100 │
│ infusion reaction) or hypersensitivity to          │ infusion reaction) or hypersensitivity to          │         │
│ trastuzumab, murine proteins, or docetaxel         │ trastuzumab, murine proteins, or docetaxel         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity to any of the study drugs,  │ Known hypersensitivity to any of the study drugs,  │     100 │
│ including the excipients, or any drugs formulated  │ including the excipients, or any drugs formulated  │         │
│ in polysorbate 80                                  │ in polysorbate 80                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Assessed by the investigator to be unable or       │ Assessed by the investigator to be unable or       │     100 │
│ unwilling to comply with the requirements of the   │ unwilling to comply with the requirements of the   │         │
│ protocol                                           │ protocol                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of exposure to the following cumulative    │ History of exposure to the following cumulative    │      98 │
│ doses of anthracyclines: Doxorubicin or liposomal  │ doses of anthracyclines: Doxorubicin or liposomal  │         │
│ doxorubicin \> 500 mg/m\^2; epirubicin \> 900      │ doxorubicin > 500 mg/m^2; epirubicin > 900 mg/m^2; │         │
│ mg/m\^2; mitoxantrone \> 120mg/m\^2 and idarubicin │ mitoxantrone > 120mg/m^2 and idarubicin > 90       │         │
│ \> 90 mg/m\^2                                      │ mg/m^2                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hormone therapy \< 7 days prior to randomization   │ Hormone therapy < 7 days prior to randomization    │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria   │   Score │
╞═══════════════════════════════════╪═════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age ≥ 18 years  │      47 │
╘═══════════════════════════════════╧═════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 98.19354838709677
OverAll Ratio: 98.59677419354838
